A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

329

Participants

Timeline

Start Date

September 21, 2015

Primary Completion Date

January 22, 2016

Study Completion Date

July 20, 2016

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.ZEBOV-Batch #1

Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

BIOLOGICAL

Ad26.ZEBOV-Batch #2

Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

BIOLOGICAL

Ad26.ZEBOV-Batch #3

Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

BIOLOGICAL

MVA-BN-Filo

MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.

BIOLOGICAL

Placebo

One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.

Trial Locations (6)

Unknown

Huntsville

San Diego

Melbourne

Peoria

Mishawaka

Rockville

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT02543268 - A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants | Biotech Hunter | Biotech Hunter